AR060222A1 - Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma - Google Patents

Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma

Info

Publication number
AR060222A1
AR060222A1 ARP070101334A ARP070101334A AR060222A1 AR 060222 A1 AR060222 A1 AR 060222A1 AR P070101334 A ARP070101334 A AR P070101334A AR P070101334 A ARP070101334 A AR P070101334A AR 060222 A1 AR060222 A1 AR 060222A1
Authority
AR
Argentina
Prior art keywords
kinase
junk
treat glaucoma
inhibitors
terminal inhibitors
Prior art date
Application number
ARP070101334A
Other languages
English (en)
Spanish (es)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR060222A1 publication Critical patent/AR060222A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP070101334A 2006-03-31 2007-03-29 Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma AR060222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/394,893 US7803824B2 (en) 2004-10-29 2006-03-31 Use of inhibitors of Jun N-terminal kinases to treat glaucoma

Publications (1)

Publication Number Publication Date
AR060222A1 true AR060222A1 (es) 2008-06-04

Family

ID=38523463

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101334A AR060222A1 (es) 2006-03-31 2007-03-29 Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma

Country Status (13)

Country Link
US (3) US7803824B2 (https=)
EP (1) EP2004158A2 (https=)
JP (1) JP5241033B2 (https=)
KR (1) KR20080108503A (https=)
CN (1) CN101415407B (https=)
AR (1) AR060222A1 (https=)
AU (1) AU2007235111B2 (https=)
BR (1) BRPI0710099A2 (https=)
CA (1) CA2644721A1 (https=)
MX (1) MX2008011319A (https=)
TW (1) TWI419694B (https=)
WO (1) WO2007117849A2 (https=)
ZA (1) ZA200807667B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
US20120077753A1 (en) * 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
CN103458970A (zh) * 2011-03-07 2013-12-18 泰莱托恩基金会 Tfeb磷酸化抑制剂及其应用
KR20160023669A (ko) * 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
AU2015281361A1 (en) * 2014-06-26 2016-11-17 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040847A1 (en) * 1996-04-26 1997-11-06 University Of Ottawa Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
KR20010083884A (ko) * 1998-10-13 2001-09-03 세파론, 인코포레이티드 눈 질환 치료제
BR9916272A (pt) 1998-12-17 2001-09-04 Hoffmann La Roche 4 e 5-alquiniloxindóis e 4 e 5-alqueniloxindóis
DE60041763D1 (de) 1999-04-23 2009-04-23 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
BR0013551A (pt) 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
KR20080028516A (ko) 1999-08-19 2008-03-31 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
WO2001091749A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
EP1193256A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
WO2003018020A1 (en) 2001-08-23 2003-03-06 Takeda Chemical Industries, Ltd. Jnk inhibitors
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
JP2003129190A (ja) 2001-10-19 2003-05-08 Sumitomo Metal Ind Ltd マルテンサイト系ステンレス鋼およびその製造方法
US20030138819A1 (en) 2001-10-26 2003-07-24 Haiqing Gong Method for detecting disease
ATE465153T1 (de) * 2002-02-28 2010-05-15 Eisai R&D Man Co Ltd Neue indazolverbindungen mit kondensiertem ring
US7351407B2 (en) * 2002-04-30 2008-04-01 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2003106455A1 (en) 2002-06-14 2003-12-24 Applied Research Systems Ars Holding N.V. Azole methylidene cyanide derivatives and their use as protein kinase modulators
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20040092568A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders

Also Published As

Publication number Publication date
CA2644721A1 (en) 2007-10-18
JP5241033B2 (ja) 2013-07-17
BRPI0710099A2 (pt) 2011-08-02
WO2007117849A3 (en) 2008-04-10
EP2004158A2 (en) 2008-12-24
WO2007117849A2 (en) 2007-10-18
US20060172991A1 (en) 2006-08-03
TWI419694B (zh) 2013-12-21
US7803824B2 (en) 2010-09-28
CN101415407A (zh) 2009-04-22
US20120004274A1 (en) 2012-01-05
KR20080108503A (ko) 2008-12-15
AU2007235111A1 (en) 2007-10-18
JP2009532373A (ja) 2009-09-10
TW200744601A (en) 2007-12-16
ZA200807667B (en) 2010-07-28
CN101415407B (zh) 2011-05-11
MX2008011319A (es) 2008-09-19
AU2007235111B2 (en) 2012-03-22
US20100311716A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
AR060222A1 (es) Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma
NO20054951L (no) Prostaglandinanaloger som EP4-reseptorantagonister
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY30060A1 (es) Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos
NO20074390L (no) Forsterket bimatoprost oye-opplosning
EA200970067A1 (ru) Агонисты ep2
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
UY29348A1 (es) Inhibición de objetivos oculares mediada por arni
ATE432323T1 (de) Bitumenzusammensetzung
BRPI0817351A2 (pt) Composição para cuidado pessoal
MX2009002239A (es) Derivados de 5-(2-furil)-1,3-tiazol util como inhibidores de fosfatidilinositol 3-cinasa.
AR059040A1 (es) Cis-4, 5- biaril-2- heterociclico imidazolinas como inhibidores de la mdm 2
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
PE20250666A1 (es) Combinaciones, mezclas y composiciones fungicidas y usos de las mismas
TW200621236A (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
BRPI0416959A (pt) composição, artigo, e, método para conferir repelência e anti-sujeira a um substrato, tendo uma ou mais superfìcies
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
AR095183A1 (es) Derivados de azetidina como agentes antiparasitarios
MX2025002677A (es) Moduladores de la alfa-1 antitripsina
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
CL2008003332A1 (es) Compuestos derivados de ciclopentano sustituido, como agentes hipotensores oculares; composicion oftalmologicamente aceptable; y uso para el tratamiento del glaucoma.
PE20090962A1 (es) Nuevas composiciones a base de taxoides
PE20220593A1 (es) Composiciones comprimidas de macitentan, metodos y usos de las mismas
ATE409491T1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
AR064015A1 (es) Inhibicion mediada por arni de acuaporina 1 para tratamiento de afecciones relacionadas con pio

Legal Events

Date Code Title Description
FA Abandonment or withdrawal